Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
J Feline Med Surg. 2023 Jul;25(7):1098612X231187691. doi: 10.1177/1098612X231187691.
The aim of the present study was to report the concurrent disorders and treatment success of cats with diabetes mellitus (DM) and arterial systolic hypertension (SH).
A retrospective longitudinal study was conducted of 17 cats with DM and SH that were examined at a university teaching hospital between 1 January 2011 and 31 December 2021. The medical records of diabetic cats were searched for the keywords 'hypertension', 'blood pressure', 'amlodipine', 'benazepril' and 'telmisartan' to identify cats with SH, which was defined as systemic arterial blood pressure (SABP) ⩾160 mmHg, documented at least twice, over several days. Comorbidities, including chronic kidney disease and hyperthyroidism, were recorded. Medications used for the treatment of SH and the SABP response to treatment were also noted.
Most cats (13/17, 76%) with DM and SH had at least one other documented concurrent illness that could contribute to SH, including chronic kidney disease (12/17 cats, 71%), hyperthyroidism (4/17, 23%) and functional adrenocortical mass secreting either aldosterone alone (1/17, 6%) or glucocorticoids, and possibly also aldosterone (1/17, 6%). Out of 17 cats, 15 (88%) were treated with amlodipine, and none were treated with an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker. Mean SABP at the time of diagnosis of SH was 210 ± 23 mmHg and was significantly higher than the mean SABP at the first and second follow-up examinations after the introduction of amlodipine treatment (175 ± 33 mmHg, = 0.008 and 172 ± 26 mmHg, = 0.01, respectively).
Cats with DM and SH should be evaluated for the presence of chronic kidney disease, hyperthyroidism and functional adrenal masses. Treatment with amlodipine appears to be effective in lowering SABP in cats with DM and SH.
本研究旨在报告并发疾病和治疗效果的糖尿病（DM）和动脉收缩高血压（SH）的猫。
对 2011 年 1 月 1 日至 2021 年 12 月 31 日期间在一所大学教学医院就诊的 17 例 DM 和 SH 猫进行回顾性纵向研究。对患有糖尿病的猫的病历进行搜索，使用关键词“高血压”、“血压”、“氨氯地平”、“贝那普利”和“替米沙坦”来识别患有 SH 的猫，其定义为系统动脉血压（SABP）≥160mmHg，至少两次记录，持续数天。记录并存疾病，包括慢性肾脏病和甲状腺功能亢进症。还记录了用于治疗 SH 的药物以及治疗对 SABP 的反应。
大多数（13/17，76%）患有 DM 和 SH 的猫至少有另一种并发疾病可能导致 SH，包括慢性肾脏病（12/17 只猫，71%）、甲状腺功能亢进症（4/17 只猫，23%）和功能性肾上腺皮质瘤，仅分泌醛固酮（1/17 只猫，6%）或糖皮质激素，可能也分泌醛固酮（1/17 只猫，6%）。17 只猫中，15 只（88%）用氨氯地平治疗，无猫用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂治疗。SH 诊断时的平均 SABP 为 210±23mmHg，明显高于氨氯地平治疗后第一次和第二次随访检查时的平均 SABP（175±33mmHg， = 0.008 和 172±26mmHg， = 0.01）。
患有 DM 和 SH 的猫应评估是否存在慢性肾脏病、甲状腺功能亢进症和功能性肾上腺肿瘤。用氨氯地平治疗似乎能有效降低患有 DM 和 SH 的猫的 SABP。
